Article Text

Download PDFPDF

Targeting B cell malignancies through human B cell receptor specific CD4 T cells
  1. Jinsheng Weng1,
  2. Flavio Egidio Baio1,
  3. Kelsey Moriarty1,
  4. Hiroki Torikai1,
  5. Hua Wang1,
  6. Zhiqiang Liu1,
  7. Sourindra Maiti1,
  8. Dongho Gwak1,
  9. Michael Popescu1,
  10. Soung-chul Cha1,
  11. Sattva S Neelapu1 and
  12. Larry Kwak1
  1. Aff1 grid.240145.60000000122914776The University of Texas MD Anderson Cancer Center Houston TX USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


The B cell receptor (BCR) expressed by a clonal B cell tumor is a tumor specific antigen (idiotype). However, the T cell epitopes within human BCRs which stimulate protective immunity still lack detailed characterization.


In this study, we identified 17 potential CD4 T cell peptide epitopes derived from BCR heavy and light chain variable region sequences. Detailed analysis revealed these CD4 T cell epitopes stimulated Th1 CD4 T cells to directly recognize the autologous tumors by secretion of IFN-γ, indicating the epitopes are processed and presented by tumors.


One BCR peptide-specific CD4 T cell line was also cytotoxic and lysed autologous tumor cells through the perforin pathway. Sequence analysis of the epitopes revealed 10 were potentially shared by multiple primary patients' tumors, and 16 had the capacity to bind more than one HLA DRB1 allele. T cells stimulated by shared epitopes recognized primary tumors expressing the same sequences on different HLA DRB1 alleles.


In conclusion, we identified multiple BCR-derived CD4 T cell epitopes with promiscuous HLA binding that are shared by up to 36% of patients, suggesting a strategy to overcome the requirement for individual preparation of therapeutic agents targeting idiotype.


This study was support by the Leukemia and Lymphoma Society Specialized Center of Research Grant #7262-08(LWK), Myeloma SPORE Grant P50CA142509, Myeloma SPORE Career Program, the Brian D. Novis research grant from the International Myeloma Foundation, and the Lady Leukemia League Research Grant.